Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options
J Jankowski, J Floege, D Fliser, M Böhm, N Marx - Circulation, 2021 - Am Heart Assoc
Patients with chronic kidney disease (CKD) exhibit an elevated cardiovascular risk
manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac …
manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac …
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
This review covers the last 80 years of remarkable progress in the development of
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …
favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 …
[HTML][HTML] Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Background Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist,
reduced albuminuria in short-term trials involving patients with chronic kidney disease …
reduced albuminuria in short-term trials involving patients with chronic kidney disease …
Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial
Background: Chronic kidney disease and type 2 diabetes are independently associated with
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD …
The renin‐angiotensin‐aldosterone system and its suppression
MK Ames, CE Atkins, B Pitt - Journal of veterinary internal …, 2019 - Wiley Online Library
Chronic activation of the renin‐angiotensin‐aldosterone system (RAAS) promotes and
perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic …
perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic …
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
U Kintscher, GL Bakris, P Kolkhof - British Journal of …, 2022 - Wiley Online Library
Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …
Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial
Background Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type
2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia …
2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia …
[HTML][HTML] Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy
Introduction FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression
in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid …
in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid …
Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial
Importance Steroidal mineralocorticoid receptor antagonists, when added to a renin-
angiotensin system blocker, further reduce proteinuria in patients with chronic kidney …
angiotensin system blocker, further reduce proteinuria in patients with chronic kidney …